Skip to main content
Journal cover image

The CHD challenge: comparing four cost-effectiveness models.

Publication ,  Journal Article
Turner, D; Raftery, J; Cooper, K; Fairbank, E; Palmer, S; Ward, S; Ara, R
Published in: Value Health
January 2011

OBJECTIVES: To compare four UK models evaluating the cost-effectiveness of interventions in coronary heart disease (CHD), exploring the relative importance of structure and inputs in accounting for differences, and the scope for consensus on structure and data. METHODS: We compared published cost-effectiveness results (incremental cost, quality-adjusted life year, and cost-effectiveness ratio) of three models conforming to the National Institute for Health and Clinical Excellence guidelines dealing with three interventions (statins, percutaneous coronary intervention, and clopidogrel) with a model developed in Southampton. Comparisons were made using three separate stages: 1) comparison of published results; 2) comparison of the results using the same data inputs wherever possible; and 3) an in-depth exploration of reasons for differences and the potential for consensus. RESULTS: Although published results differed by up to 73% (for statins), standardization of inputs (stage 2) narrowed these gaps. Greater understanding of the reasons for differences was achieved, but a consensus on preferred values for all data inputs was not reached. CONCLUSIONS: We found that published guidance on methods was important to reduce variation in important model inputs. Although the comparison of models did not lead to consensus for all model inputs, it provided a better understanding of the reasons for these differences, and enhanced the transparency and credibility of all models. Similar comparisons would be aided by fuller publication of models, perhaps through detailed web appendices.

Duke Scholars

Published In

Value Health

DOI

EISSN

1524-4733

Publication Date

January 2011

Volume

14

Issue

1

Start / End Page

53 / 60

Location

United States

Related Subject Headings

  • United Kingdom
  • Ticlopidine
  • Sensitivity and Specificity
  • Reproducibility of Results
  • Quality-Adjusted Life Years
  • Platelet Aggregation Inhibitors
  • Models, Econometric
  • Middle Aged
  • Male
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Turner, D., Raftery, J., Cooper, K., Fairbank, E., Palmer, S., Ward, S., & Ara, R. (2011). The CHD challenge: comparing four cost-effectiveness models. Value Health, 14(1), 53–60. https://doi.org/10.1016/j.jval.2010.10.009
Turner, David, James Raftery, Keith Cooper, Eleanor Fairbank, Stephen Palmer, Sue Ward, and Roberta Ara. “The CHD challenge: comparing four cost-effectiveness models.Value Health 14, no. 1 (January 2011): 53–60. https://doi.org/10.1016/j.jval.2010.10.009.
Turner D, Raftery J, Cooper K, Fairbank E, Palmer S, Ward S, et al. The CHD challenge: comparing four cost-effectiveness models. Value Health. 2011 Jan;14(1):53–60.
Turner, David, et al. “The CHD challenge: comparing four cost-effectiveness models.Value Health, vol. 14, no. 1, Jan. 2011, pp. 53–60. Pubmed, doi:10.1016/j.jval.2010.10.009.
Turner D, Raftery J, Cooper K, Fairbank E, Palmer S, Ward S, Ara R. The CHD challenge: comparing four cost-effectiveness models. Value Health. 2011 Jan;14(1):53–60.
Journal cover image

Published In

Value Health

DOI

EISSN

1524-4733

Publication Date

January 2011

Volume

14

Issue

1

Start / End Page

53 / 60

Location

United States

Related Subject Headings

  • United Kingdom
  • Ticlopidine
  • Sensitivity and Specificity
  • Reproducibility of Results
  • Quality-Adjusted Life Years
  • Platelet Aggregation Inhibitors
  • Models, Econometric
  • Middle Aged
  • Male
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors